Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of Four New Patents for Microcyn(R) Technology

• U.S. Patent for Treatment of Second- and Third-Degree Burns; U.S. and Canadian Patents for Treatment of Peritonitis; Chinese Patent for Solution Containing Hypochlorous Acid and Its Methods of Use

PETALUMA, Calif., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries, today announced the allowance of four new U.S. and international patents for the company's flagship technology, Microcyn®. These include a U.S. patent for treatment of second- and third-degree burns; U.S. and Canadian patents for treatment of peritonitis; and a Chinese patent for the Microcyn solution and its methods of use.  The U.S. patent directed to peritonitis issued today as U.S. Patent No. 8,834,445, while the second- and third-degree burn U.S. patent will issue on September 23, 2014. The exact dates of issuance for the Chinese and Canadian patents are yet to be determined.  

Dr. Bob Northey, Oculus senior vice president for research and development said: "Our intellectual property portfolio is growing and is perfectly synced with our continued expansion, both in terms of product portfolio and international footprint.  Our Microcyn-based products are now commercialized in more than thirty-three countries around the globe with a target of forty-one by year's end. The empirical evidence documenting Microcyn's efficacy in the treatment of both burns and peritonitis is highly compelling, and will further fortify our marketing efforts for those indications."

The latest-issued patents join an intellectual property estate (either owned or licensed to Oculus) that now includes 41 issued and allowed patents (seven in the United States and 38 foreign patents) as well 92 pending applications (both U.S. and foreign) directed to chemical compositions, apparatuses, methods of manufacturing and therapeutic uses.

About Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company's products are used to treat patients in surgical/advanced wound management, dermatology, women's health and animal health markets; addressing the unmet medical needs of these markets, while raising the standard of patient care and lowering overall healthcare costs.  The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company"). These forward-looking statements are identified by the use of words such as "accelerate," "preparing," and "launch," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its annual report on Form 10-K for the year ended March 31, 2014. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Oculus® and Microcyn® Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners. High-resolution product photos are available. Please call or email request.

CONTACT: Media and Investor Contact:

         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
         dmcfadden@oculusis.com

Released September 16, 2014